Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

menu

Biostatistics and Computational Biology

URMC / Department of Biostatistics and Computational Biology / People & Research / Faculty / Shirley Eberly, MS

 

Shirley Eberly, MS

Research Associate

As a member of the research faculty, I am involved with statistical analysis of clinical research data and manuscript preparation, primarily for large scale clinical trials for the treatment of Parkinson's disease and Huntington disease. Other studies in which I have been involved include examinations of genetic factors affecting the recurrence of coronary events after myocardial infarction; possible interventions to reduce environmental lead exposures in young children; and the effect of pacifier use on breastfeeding duration and complications.

Selected Publications:

  • Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; for the Huntington Study Group PHAROS Investigators (2013). Relationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease. JAMA Neurology 70(11):1382-1388. PMID: 24000094 [PubMed – indexed for MEDLINE]
  • Moscovitch-Lopatin M, Goodman RE, Eberly S, et al. (2013). HTRF Analysis of Soluble Huntingtin in PHAROS PBMCs. Neurology 81(13):1134-1140. PMCID: PMC37959598 [Available on 2014/9/24]
  • Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I, on behalf of the LABS-PD investigators (2013). Movement Disorder Society Unified Parkinson Disease Rating Scale Experiences in Daily Living: Longitudinal Changes and Correlation with Other Assessments. Movement Disorders 28(14):1980-1986. PMID: 24123385 [PubMed – in process]
  • Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I (2013). Characterization of the Huntington Intermediate CAG Repeat Expansion Phenotype in PHAROS. Neurology 80(22):2022-2027. PMCID: PMC3716408 [Available on 2014/5/28]
  • Wills A-M, Eberly S, Tennis M, Lang A, Messing S, Togasaki D, Tanner C, Kamp C, Chen J-F, Oakes D, McDermott M, Schwarzschild M (2013). Caffeine Consumption and Risk of Dyskinesia in CALM-PD. Movement Disorders  28(3): 380-383.
  • Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I (2012). Dopamine Transporter Imaging is Associated with Long-Term Outcomes in Parkinson’s Disease. Movement Disorders 27(11):1392-1397.  PMID: 22976926 [PubMed – in process]
  • Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K. (2012). Impaired Olfaction and Other Prodromal Features in the Parkinson At-Risk Syndrome Study.  Movement Disorders 27(3):406-412 PMID: 22237833 [PubMed – indexed for MEDLINE]
  • Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H, for the Parkinson Study Group DATATOP Investigators (2011). Serum Cholesterol and the Progression of Parkinson’s Disease: Results from DATATOP. PloS ONE 6(8):e22854. PMCID: PMC3154909
  • Humiston SG, Bennett NM, Long C, Eberly S, Arvelo L, Stankaitis J, Szilagyi PG (2011).  Increasing Inner-City Adult Influenza Vaccination Rates:  A Randomized Controlled Trial.  Public Health Reports 126(Supplement 2):39-47.  PMCID:  PMC3113429
  • Schwarzschild M, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. (2011). Urate and Probability of Dopaminergic Deficit in Early Parkinson’s Disease.  Movement Disorders 26(10): 1864-1868.
  • Rushton EK, Jiang J, Leonard SS, Eberly S, Castranova V, Biswas P, Elder A, Han X, Gelein R, Finkelstein J, Oberdöerster G. (2010). Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics.  Journal of Toxicology and Environmental Health 73(5-6):445-461.  PMID: 20155585 [PubMed - indexed for MEDLINE]
  • Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I. (2009). A Comparison of Treatment Thresholds in Two Large Parkinson’s Disease Clinical Trial Cohorts.  Movement Disorders 24(16):2370-2378.  PMID: 19908310 [PubMed - indexed for MEDLINE]
  • Ravina B, Tanner C, DiEuliis D, Eberly, S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, The Parkinson Study Group (2009). A Longitudinal Program for Biomarker Development in Parkinson’s disease: A Feasibility Study. Movement Disorders 24(14):2081-2090.  PMID: 19691116 [PubMed - indexed for MEDLINE]
  • Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA (2009). Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease.  Archives of Neurology 66(12):1460-1468 (doi:10.1001/archneurol.2009.247).  PMCID: PMC2795011
  • Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, Huntington Study Group (2009). Dietary Intake in Adults at Risk for Huntington Disease: Analysis of PHAROS Research Participants. Neurology 73:385-392.  PMCID: PMC2725927
  • Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A and Jankovic J (2008). A Study of Chorea after Tetrabenazine Withdrawal in Patients with Huntington Disease. Clinical Neuropharmacology 31(3):127-133.  PMID: 18520979 [PubMed - indexed for MEDLINE]
  • Wyman PA, Moynihan J, Eberly S, Cox C, Cross W, Jin X, Caserta MT (2007). Association of Family Stress with Natural Killer Cell Activity and the Frequency of Illnesses in Children. Archives of Pediatric and Adolescent Medicine 161(3):228-234.
  • Elder A, Couderc J-P, Gelein R, Eberly S, Cox C, Xia X, Zareba W, Hopke P, Watts W, Kittelson D, Frampton M, Utell M, Oberdoerster G (2007). Effects of On-road Highway Aerosol Exposures on Autonomic Responses in Aged Spontaneously Hypertensive Rats. Inhalation Toxicology 19(1):1-12.
  • Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I (2006). Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. Journal of the Neurological Sciences 248(1-2):78-83.
  • Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, the Parkinson Study Group TEMPO & PRESTO Investigators (2006). Safety of Rasagiline in Elderly Parkinson’s Disease Patients. Neurology 66(9):1427-1429.
  • Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group (2006). Rasagiline Improves Quality of Life in Patients with Early Parkinson Disease Movement Disorders 21(5):616-623.
  • Moss, A.J., Ryan, D., Oakes, D., Goldstein, R.E., Greenberg, H., Bodenheimer, M.M., Brown, M.W., Case, R.B., Dwyer, Jr., E.M., Eberly, S.W., Francis, C.W., et al. (2005). Atherosclerotic Risk Genotypes and Recurrent Coronary Events After Myocardial Infarction. American Journal of Cardiology 96, 177-182.